Aerpio Pharmaceuticals, Inc.

Aerpio Pharmaceuticals, Inc.

ARPO

ARPOAerpio Pharmaceuticals, Inc. US flag

NASDAQ Capital Market

2.20

USD

-0.02

- -

53.67MMarket Cap

Aerpio Pharmaceuticals, Inc.

ARPO

(NASDAQ Capital Market)

Recent

price

2.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Dermata Therapeutics, Inc. (DRMAW)
Unity Biotechnology, Inc. (UBX)
Aprea Therapeutics, Inc. (APRE)
AnGes, Inc. (AMGXF)
Fortrea Holdings Inc. (FTRE)
XTL Biopharmaceuticals Ltd. (XTLB.TA)
Business: Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) is a clinical-stage biopharmaceutical company focused on developing treatments for vascular diseases and inflammation. The company advances novel therapeutics targeting the hypoxia-inducible factor (HIF) pathway, including its lead candidate AER-901, a small molecule inhibitor of prolyl hydroxylase domain (PHD) enzymes designed to treat diabetic retinopathy and other inflammatory conditions; AER-270, a selective stabilizer of HIF-1alpha for potential applications in pulmonary hypertension; and earlier-stage programs exploring stabilized HIF-1alpha modulators for oncology and fibrosis. Aerpio's pipeline emphasizes orally bioavailable small molecules that modulate oxygen-sensing pathways to address unmet needs in ophthalmology, pulmonology, and immunology, with research services previously offered through its former contract research subsidiary. Founded in 2007 and headquartered in Blue Ash, Ohio, the company operates primarily in the United States, with clinical trials conducted across North America and Europe targeting patients with rare vascular disorders and chronic inflammatory diseases. In recent developments, Aerpio completed a strategic restructuring in 2021 by spinning off its contract research organization into Aadi Bioscience, Inc., which subsequently listed on NASDAQ (AADI) and advanced its lead drug FYARRO for rare cancers; the company has since focused exclusively on its remaining small molecule portfolio, with no major funding rounds, acquisitions, partnerships, or new product launches announced in the last 1-2 years as of December 2025.

Company News